CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a note issued to investors on Thursday. The firm set a “sell” rating on the stock.

CEL-SCI Trading Up 1.2 %

CEL-SCI stock opened at $0.41 on Thursday. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00. CEL-SCI has a 12-month low of $0.36 and a 12-month high of $3.08. The firm has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.71 and a beta of 0.65. The firm has a 50 day moving average of $0.59 and a 200 day moving average of $0.93.

Institutional Investors Weigh In On CEL-SCI

A number of institutional investors have recently bought and sold shares of the business. Thoroughbred Financial Services LLC boosted its stake in shares of CEL-SCI by 140.9% in the second quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares during the period. Renaissance Technologies LLC boosted its stake in CEL-SCI by 29.9% in the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after purchasing an additional 40,000 shares during the period. Calton & Associates Inc. purchased a new stake in CEL-SCI during the 3rd quarter valued at approximately $50,000. Plotkin Financial Advisors LLC bought a new stake in shares of CEL-SCI during the third quarter valued at approximately $98,000. Finally, Geode Capital Management LLC lifted its holdings in shares of CEL-SCI by 9.6% in the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after buying an additional 53,879 shares in the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.